Updates in Myelofibrosis
Top Stories
Incidence and Predictors of Thrombotic Events in Secondary Myelofibrosis

Researchers found that in patients with secondary myelofibrosis (SMF), the annual incidence of thrombotic events (TEs) was 2.3% of patients per year. 

Hematology Advisor
2d ago
Novel Liposome Formulation of Irinotecan Plus Chemotherapy Improved Survival Outcomes for Locally Advanced and Metastatic Pancreatic Cancer

HR070803, a liposome formulation of irinotecan, improved survival outcomes for patients with locally advanced or metastatic pancreatic cancer who have previously failed on gemcitabine-based therapy

Oncology Learning Network
2w ago
Elevated Plasma EDA Fibronectin in Primary Myelofibrosis is Determined by High Allele Burden of JAK2V617F Mutation and Strongly Predicts Splenomegaly Progression

EDA-FN expression in primary myelofibrosis may represent the first marker of disease progression, and a novel target to treat splenomegaly.

Frontiers in Oncology
1w ago
Neoadjuvant Immunotherapy Improves Outlook in High-Risk Melanoma

Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring

MD Anderson
2w ago
Momelotinib Bests Danazol in Symptomatic, Anemic Myelofibrosis

Momelotinib proved superior to danazol for key outcomes in a phase 3 trial of patients with symptomatic and anemic myelofibrosis.

Cancer Therapy Advisor
3m ago